摘要
目的：观察溶栓新药重组链激酶（ｒ－ＳＫ）在急性心肌梗死（ＡＭＩ）静脉溶栓治疗中的临床疗效和不良反应。方法：采用平行随机单盲对照的研究方法，以尿激酶（ＵＫ）为对照比较ｒ－ＳＫ对ＡＭＩ的溶栓治疗效果和不良反应。结果：ｒ－ＳＫ１５０万Ｕ对ＡＭＩ的溶栓再通率为８４．４％，而ＵＫ１５０万Ｕ仅为５６．７％（Ｐ＜０．０５）。不良反应除发冷外其他方面两组无差异。结论：国产ｒ－ＳＫ是一个血管再通率高，不良反应及出血并发症低，安全有效的溶栓药物。
Objective:To observe the efficacy and safety of intravenous recombinant streptokinase (r SK) in treatment of acute myocardial infarction (AMI).Methods:In this single blind,randomized,parallel controlled study,we compared the efficacy and safety of r SK with those of urokinase (UK).Results:The reperfusion rate of r SK 1.5 million units was 84.4% but that of UK 1.5 million units was only 56.7% (P<0.05).Complications were similiar between two groups except feeling cold.Conclusion:China made r SK is a safe and effective thrombolytic agent.
出处
《山西医药杂志》
CAS
1999年第3期190-191,共2页
Shanxi Medical Journal
关键词
心肌梗塞
重组链激酶
溶栓疗法
acute myocardial infarction recombinant streptokinase thrombolytic therapy
